Insulin for All Act of 2023
Source: Congress.gov ·
295 words in original text
What This Bill Does
This bill limits the price that insulin manufacturers can charge for insulin sold in the United States. Manufacturers would not be allowed to charge more than $20 per 1000 units of insulin, regardless of how the insulin is packaged or delivered.
Who It Affects
- Insulin manufacturers who sell products in the United States
- People who need to buy insulin
Key Provisions
- Manufacturers of insulin cannot charge more than $20 per 1000 units of insulin for products sold in the United States (Sec. 2(a))
- The $20 price limit applies regardless of whether the insulin comes in vials, pens, cartridges or other forms of delivery (Sec. 2(a))
- The price limitation applies to insulin that is licensed and continues to be sold under federal law (Sec. 2(b))
What Changes
If this becomes law, insulin manufacturers would be prohibited from charging more than $20 per 1000 units for insulin sold in the United States. Any pricing above this limit would violate this law.
Important Definitions
"Insulin" means insulin that is licensed under federal law and continues to be marketed under that license (Sec. 2(b)).
Effective Date
Not specified in bill text
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.